MET alterations in advanced non-small cell lung cancer
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference160 articles.
1. The Effect of Advances in Lung-Cancer Treatment on Population Mortality;Howlader;N. Engl. J. Med.,2020
2. Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer;Scagliotti;J. Clin. Oncol.,2015
3. Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung;Spigel;J. Clin. Oncol.,2017
4. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal;Yoshioka;Ann. Oncol.,2015
5. Mok TSK, Park K, Geater SL, et al. A Randomized Phase (PH) 2 Study with Exploratory Biomarker Analysis of Ficlatuzumab (F) A Humanized Hepatocyte Growth Factor (HGF) Inhibitory MAB in Combination with Gefitinib (G) Versus G in Asian Patients (PTS) with Lung Adenocarcinoma (LA). Ann Oncol. 2012;23:ix391. doi:10.1016/S0923-7534(20)33782-0.
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. L’immunohistochimie c-Met en oncologie thoracique, un nouvel enjeu pour le pathologiste;Revue Francophone des Laboratoires;2023-12
2. MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target;Cancers;2023-09-28
3. Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States;Pharmacological Research;2023-08
4. MET-Targeting Anticancer Drugs—De Novo Design and Identification by Drug Repurposing;Drugs and Drug Candidates;2023-07-18
5. Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?;International Journal of Molecular Sciences;2023-06-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3